The adjustment in price target by Wedbush reflects a nuanced view on Rallybio's future performance. While the Outperform rating indicates a positive outlook on the company's stock, the reduction in price target suggests a tempering of expectations regarding its short-term price potential. This could lead to mixed reactions in the market, with the positive rating potentially offsetting negative sentiment from the lowered price target.